-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $44

Benzinga·05/09/2025 17:53:18
Listen to the news
Goldman Sachs analyst Salveen Richter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and lowers the price target from $51 to $44.